Cited by

• Searching for the Chokehold of NRAS Mutant Melanoma.

  Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K, Ortiz-Urda S. Posch C, et al. J Invest Dermatol. 2016 Jul;136(7):1330-1336. doi: 10.1016/j.jid.2016.03.006. Epub 2016 May 7. J Invest Dermatol. 2016. PMID: 27160069 Free PMC article. Review.
• Neoadjuvant treatment for stage III and IV cutaneous melanoma.

  Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Gorry C, et al. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2. Cochrane Database Syst Rev. 2023. PMID: 36648215 Free PMC article.
• Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies.

  Han X, Ge P, Liu S, Yang D, Zhang J, Wang X, Liang W. Han X, et al. Front Pharmacol. 2023 Jul 13;14:1163805. doi: 10.3389/fphar.2023.1163805. eCollection 2023. Front Pharmacol. 2023. PMID: 37521468 Free PMC article.
• NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma.

  Ibrahim M, Illa-Bochaca I, Jour G, Vega-Saenz de Miera E, Fracasso J, Ruggles K, Osman I, Schober M. Ibrahim M, et al. Cancer Res. 2025 Jun 10:10.1158/0008-5472.CAN-24-3904. doi: 10.1158/0008-5472.CAN-24-3904. Online ahead of print. Cancer Res. 2025. PMID: 40494652
• Neutrophil extracellular trap related risk score exhibits crucial prognostic value in skin cutaneous melanoma, associating with distinct immune characteristics.

  Zhang H, Bi X, Yan P, Wang C. Zhang H, et al. Skin Res Technol. 2024 Aug;30(8):e70008. doi: 10.1111/srt.70008. Skin Res Technol. 2024. PMID: 39167030 Free PMC article.